Take Solutions Ltd
Take Solutions operates with a strong equity base, as evidenced by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company maintains a current ratio of 1.48, suggesting it has sufficient short-term assets to cover its liabilities. However, the operating cash flow of -164.49 million INR indicates a cash outflow from operations, which could be a concern for liquidity. The free cash flow of 7.44 million INR is positive but relatively small, suggesting limited flexibility for reinvestment or shareholder returns. The company's profitability is highlighted by a return on equity (ROE) of 1.8253 and a return on assets (ROA) of 1.0271, both of which are strong indicators of efficient use of equity and assets. These metrics suggest that Take Solutions is generating solid returns for its shareholders and effectively utilizing its asset base. Take Solutions' revenue is not disclosed in the latest financial snapshot, but the company's global client base includes large and small biopharmaceutical and device companies, as well as U.S. federal agencies like the CDC and the DoD. This diverse client portfolio may help mitigate geographic and sector-specific risks. The company's growth trajectory is not clearly defined in the latest financial data, as revenue is reported as 0.0 INR. However, the positive net income of 374.67 million INR suggests that the company is profitable. The absence of capital expenditure and the presence of a small free cash flow indicate that the company may be in a maintenance phase rather than an expansion phase. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's strong equity position and lack of long-term debt contribute to its low liquidity risk. The dilution risk is also low, suggesting that the company is not expected to issue additional shares in the near term. Recent events and filings do not show any significant changes in the company's financial or operational status. The company's financial snapshot does not include any recent events or transcripts, but the absence of negative flags suggests that the company is operating within normal parameters.
Business. Take Solutions Limited provides contract research organization (CRO) services to pharmaceutical, biotech, and medical device companies, offering clinical research, data sciences, and regulatory affairs services, with clients including the CDC and U.S. Department of Defense.
Classification. Take Solutions is classified under the Healthcare sector, specifically in the Biotechnology & Medical Research industry, with a confidence level of 0.92.
- Take Solutions has a strong equity position with no long-term debt, contributing to low liquidity risk.
- The company's ROE and ROA are strong, indicating efficient use of equity and assets.
- The company's diverse client base, including U.S. federal agencies, may help mitigate geographic and sector-specific risks.
- The positive net income suggests profitability, but the operating cash flow is negative, indicating potential liquidity concerns.
- The company's low dilution risk suggests no immediate pressure to issue additional shares.
- --
- ## RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.